Lixte Biotechnology closed its acquisition of NOMAD Transportable Power Systems via merger, issuing 50,366.07 shares of Series D Convertible Preferred (convertible at $1.00) and 2,992,041 common shares at closing, with capacity for up to 50,500 preferred and roughly 3,000,005 common in total. An amendment updated fractional-share handling and the consideration schedule. Concurrently, Lixte signed a Registration Rights Agreement to register resales of the issued shares under specified timelines and secured Stockholder Support Agreements to back key post-merger approvals, including preferred conversion and board elections.

Agreement 1: Lixte Biotechnology Completes Merger With NOMAD; Issues 50.4K Series D Preferred and 3.0M Shares

• Agreement type: Merger Agreement and Amendment No. 1
• Counterparty: NOMAD Transportable Power Systems
• Signed / Effective: Jun 11 2026 / Jul 01 2026
• Duration / Termination: Until closing
• Reason: Transform business via acquisition of mobile power platform

Agreement 2: Lixte Grants Resale Rights to NOMAD Holders With Post-Approval Registration Timeline

• Agreement type: Registration Rights Agreement
• Counterparty: Holders of NOMAD common stock
• Signed / Effective: Jul 01 2026 / Jul 01 2026
• Duration / Termination: Until resale registration completed
• Reason: Provide liquidity to former NOMAD holders

Agreement 3: Lixte Secures Stockholder Support Commitments for Post-Merger Approvals

• Agreement type: Stockholder Support Agreement
• Counterparty: Supporting Stockholders of Lixte
• Signed / Effective: Jul 01 2026 / Jul 01 2026
• Duration / Termination: Until stockholder vote
• Reason: Secure votes for conversion and governance approvals

Original SEC Filing: LIXTE BIOTECHNOLOGY HOLDINGS, INC. [ LIXT ] - 8-K - Jul. 02, 2026